8 results match your criteria: "Clinic E Cavell and University of Brussels[Affiliation]"
Alternating Cystoscopy with Bladder EpiCheck in the Surveillance of Low-Grade Intermediate-Risk NMIBC: A Cost Comparison Model.
Bladder Cancer
August 2021
Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Background: Bladder cancer surveillance is invasive, intensive and costly. Patients with low grade intermediate risk non-muscle invasive bladder cancer (NMIBC) are at high risk of recurrence.
Objective: The objective of this model is to compare the cost of a strategy to alternate surveillance with cystoscopy and a urine marker, Bladder EpiCheck, to standard surveillance.
Trends in urologic oncology clinical practice and medical education under COVID-19 pandemic: An international survey of senior clinical and academic urologists.
Urol Oncol
December 2020
Department of Urology, Chaim Sheba Medical Center, Ramat Gan, Israel, The Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Objective: Ad-hoc guidelines for managing the COVID-19 pandemic are published worldwide. We investigated international applications of such policies in the urologic-oncology community.
Methods: A 20-item survey was e-mailed via SurveyMonkey to 100 international senior urologic-oncology surgeons.
Purpose: Lower serum testosterone levels correlate with improved cause specific survival and longer time to progression in year 1 of continuous androgen deprivation in men with prostate cancer. ICELAND was a large European study demonstrating the efficacy of leuprorelin (Eligard®) during continuous androgen deprivation. In this post hoc analysis we investigated serum testosterone levels within year 1 of continuous androgen deprivation to determine survival and time to progression.
View Article and Find Full Text PDFRe: Zhihua Lu, Guiting Lin, Amanda Reed-Maldonado, Chunxi Wang, Yung-Chin Lee, Tom F. Lue. Low-intensity Extracorporeal Shock Wave Treatment Improves Erectile Function: A Systematic Review and Meta-analysis. Eur Urol 2017;71:223-33: Low-intensity Extracorporeal Shock Wave Treatment of Erectile Dysfunction: Does the Shadow Exceed the Light?
Eur Urol
May 2017
Department of Urology, Vita e Salute San Raffaele University, Milan, Italy.
Testosterone Therapy in Men With Prostate Cancer.
Eur Urol
May 2016
Department of Urology, Universita Vita-Salute San Raffaele, Milan, Italy.
Context: The use of testosterone therapy in men with prostate cancer was previously contraindicated, although recent data challenge this axiom. Over the past 2 decades, there has been a dramatic paradigm shift in beliefs, attitude, and treatment of testosterone deficiency in men with prostate cancer.
Objective: To summarize and analyze current literature regarding the effect of testosterone replacement in men with prostate cancer.
Intermittent Versus Continuous Androgen Deprivation Therapy in Patients with Relapsing or Locally Advanced Prostate Cancer: A Phase 3b Randomised Study (ICELAND).
Eur Urol
April 2016
Institut de Recherche Clinique, Université catholique de Louvain, Brussels, Belgium.
Background: Intermittent androgen deprivation (IAD) has received increasing attention; however, the current literature is still limited, especially in nonmetastatic prostate cancer (PCa), and the relative efficacy and safety benefits of IAD versus continuous androgen deprivation (CAD) remain unclear.
Objective: To add to the knowledge base regarding efficacy and potential benefits, including reduced side effects and improved quality of life (QoL), of IAD versus CAD in patients with nonmetastatic relapsing or locally advanced PCa.
Design, Setting, And Participants: A 42-mo phase 3b open-label randomised study in 933 patients from 20 European countries.
Corrigendum to "Reply to Ruth E. Langley, Patricia Price and Paul D. Abel's Letter to the Editor re: Claude C. Schulman, Jacques Irani, Juan Morote, et al. Androgen-Deprivation Therapy in Prostate Cancer: A European Expert Panel Review. Eur Urol Suppl 2010;9:675-91" [Eur Urol 2011;59:e26].
Eur Urol
July 2011
Clinic E. Cavell and University of Brussels, rue Edith Cavell 32, Brussels, 1180, Belgium. Electronic address:
Testosterone measurement in patients with prostate cancer.
Eur Urol
July 2010
Clinic E. Cavell and University of Brussels, Brussels, Belgium.
Context: Serum testosterone measurement has no widely accepted place in the management of patients with prostate cancer (PCa). However, several potential clinical applications of serum testosterone determination can be envisaged.
Objective: To review the role of testosterone and the androgen axis in the natural history of PCa and evaluate the evidence for the clinical application of serum testosterone measurement in patient screening, diagnosis, and management.